Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 24.40B | 22.97B | 19.80B | 19.29B | 17.60B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.40B | 22.97B | 19.80B | 19.29B | 17.60B |
| Cost of Revenue | 3.93B | 3.27B | 3.58B | 3.37B | 3.01B |
| Gross Profit | 20.46B | 19.71B | 16.22B | 15.92B | 14.59B |
| SG&A Expenses | 3.13B | 3.43B | 2.93B | 3.46B | 2.74B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.31B | 10.52B | 10.02B | 10.63B | 9.22B |
| Operating Income | 13.09B | 12.46B | 9.78B | 8.66B | 8.39B |
| Income Before Tax | 8.41B | 9.25B | 8.85B | 8.27B | 7.23B |
| Income Tax Expenses | 1.96B | 2.15B | 1.45B | 1.63B | 1.65B |
| Earnings from Continuing Operations | 6.45B | 7.10B | 7.40B | 6.64B | 5.58B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.45B | 7.10B | 7.40B | 6.64B | 5.58B |
| EBIT | 13.09B | 12.46B | 9.78B | 8.66B | 8.39B |
| EBITDA | 13.64B | 12.99B | 10.29B | 9.25B | 8.86B |
| EPS Basic | 7.23 | 7.95 | 8.27 | 7.39 | 6.22 |
| Normalized Basic EPS | 9.03 | 8.91 | 6.79 | 6.19 | 5.75 |
| EPS Diluted | 7.22 | 7.94 | 8.26 | 7.39 | 6.21 |
| Normalized Diluted EPS | 9.02 | 8.90 | 6.78 | 6.19 | 5.74 |
| Average Basic Shares Outstanding | 891.90M | 892.40M | 894.50M | 898.00M | 896.90M |
| Average Diluted Shares Outstanding | 893.40M | 893.70M | 895.90M | 898.00M | 898.80M |
| Dividend Per Share | 1.73 | 1.73 | 1.73 | 1.50 | 1.50 |
| Payout Ratio | 23.89% | 21.79% | 20.93% | 20.27% | 24.11% |